Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.62 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | VCP | P55072 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.36 |
| ▸ | ALB | P02768 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12985338 | 0.92 | FGFR1 (0.57) | FGFR1SLC22A6LMNAMEN1ALDH1A1 | |
| SCHEMBL10475501 | 0.88 | SLC22A6 (0.56) | FGFR1SLC22A6LMNAMEN1ALDH1A1 | |
| SCHEMBL10015805 | 0.85 | FGFR1 (0.53) | FGFR1SLC22A6LMNAMEN1ALDH1A1 | |
| SCHEMBL23023826 | 0.84 | FGFR1 (0.52) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL15046004 | 0.83 | FGFR1 (0.71) | FGFR1SLC22A6LMNAMEN1ALDH1A1 | |
| SCHEMBL25521527 | 0.83 | FGFR1 (0.71) | FGFR1SLC22A6LMNAMEN1ALDH1A1 | |
| SCHEMBL10475721 | 0.83 | SLC22A6 (0.53) | FGFR1SLC22A6LMNAMEN1ALDH1A1 | |
| SCHEMBL10475678 | 0.83 | FGFR1 (0.51) | FGFR1SLC22A6LMNAMEN1ALDH1A1 | |
| SCHEMBL10196377 | 0.83 | FGFR1 (0.51) | FGFR1SLC22A6LMNAMEN1ALDH1A1 | |
| SCHEMBL14143074 | 0.82 | PDE3A (0.57) | FGFR1SLC22A6LMNAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110676-B2 | Prodrugs activated by RNA-dependent DNA-polymerases | PROTERA S.R.L. (IT) | 2012-02-07 | — | — | US | claimed |
| US-20080300215-A1 | Prodrugs Activated by Rna-Dependent Dna-Polymerases | PROTERA S.R.L. (IT) | 2008-12-04 | — | — | US | claimed |
| EP-1778254-A2 | PRODRUGS ACTIVATED BY RNA-DEPENDENT DNA-POLYMERASES | Protera S.R.L. (IT) | 2007-05-02 | — | — | EP | claimed |
| WO-2006013203-A2 | PRODRUGS ACTIVATED BY RNA-DEPENDENT DNA-POLYMERASES | PROTERA S.R.L. (IT) | 2006-02-09 | — | — | WO | claimed |
| EP-0167385-B1 | ANTIVIRAL COMPOUNDS, TREATMENT AND FORMULATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-03-18 | — | — | EP | claimed |
| EP-0167385-A2 | Antiviral compounds, treatment and formulations | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-01-08 | — | — | EP | claimed |
| EP-0135713-A2 | Antiviral combinations | THE WELLCOME FOUNDATION LIMITED (GB) | 1985-04-03 | — | — | EP | claimed |
| US-8110676-B2 | Prodrugs activated by RNA-dependent DNA-polymerases | PROTERA S.R.L. (IT) | 2012-02-07 | — | — | US | disclosed |
| US-20080300215-A1 | Prodrugs Activated by Rna-Dependent Dna-Polymerases | PROTERA S.R.L. (IT) | 2008-12-04 | — | — | US | disclosed |
| WO-2008082601-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| EP-1778254-A2 | PRODRUGS ACTIVATED BY RNA-DEPENDENT DNA-POLYMERASES | Protera S.R.L. (IT) | 2007-05-02 | — | — | EP | disclosed |
| US-20070025910-A1 | Anticancer therapy | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2007-02-01 | — | — | US | disclosed |
| WO-2006013203-A2 | PRODRUGS ACTIVATED BY RNA-DEPENDENT DNA-POLYMERASES | PROTERA S.R.L. (IT) | 2006-02-09 | — | — | WO | disclosed |
| EP-0375329-A2 | Antiviral pyrimidine and purine compounds, process for their preparation and pharmaceutical compositions containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-06-27 | — | — | EP | disclosed |
| EP-0349243-A2 | Antiviral combinations and compounds therefor | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-03 | — | — | EP | disclosed |
| US-4758572-A | Antiviral combinations | BURROUGHS WELLCOME CO. (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0167385-A2 | Antiviral compounds, treatment and formulations | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-01-08 | — | — | EP | disclosed |
| EP-0167385-A2 | Antiviral compounds, treatment and formulations | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-01-08 | — | — | EP | disclosed |
| EP-0135713-A2 | Antiviral combinations | THE WELLCOME FOUNDATION LIMITED (GB) | 1985-04-03 | — | — | EP | disclosed |
| US-4508898-A | Antiviral triazine compounds | SYNTEX (U.S.A.) INC. | 1985-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300215-A1 | Prodrugs Activated by Rna-Dependent Dna-Polymerases | TERT, POLRMT, POLI | FGFR1 4530/4885SLC22A6 4696/4885LMNA 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.